DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/c5zwd6/zonegran) has announced the addition of GlobalData's new report "Zonegran (Epilepsy) - Forecast and Market Analysis to 2022" to their offering.
PharmaPoint Drug Evaluation report, Zonegran (Epilepsy) - Forecast and Market Analysis to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period.
Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
Zonegran (zonisamide) is an AED that was originally developed by Dainippon Sumitomo Pharma and was launched under the brand name Excegran in Japan in 1989. It was initially marketed by Elan in the United States as Zonegran starting in 2000, before Elan transferred its interests in the drug to Eisai in 2004. Eisai also markets Zonegran in Asia (including China) and Europe. Zonisamide is chemically classified as a sulfonamide and is unrelated to other marketed anticonvulsants. Although the precise MOA of zonisamide is unknown, it is thought to convey its anticonvulsant properties through action at sodium and calcium channels.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
See the original post:
Research and Markets: PharmaPoint Drug Evaluation Report - Zonegran ( Epilepsy ) - Forecast and Market Analysis to 2022